BCMA Targeted Therapies Market By Product Type (CAR-T Cell Therapies, Bispecific Antibodies and T-Cell Engagers, Antibody-Drug Conjugates); By Treatment Application (Late-Line Relapsed or Refractory Multiple Myeloma, Earlier-Line Relapsed Multiple Myeloma); By End User (Hospitals and Academic Medical Centers, Specialty Oncology and Hematology Clinics, Ambulatory and Outpatient Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

BCMA Therapies Expand the Treatment Window in Multiple Myeloma

The Global BCMA Targeted Therapies Market was valued at USD 9.10 billion in 2025 and is projected to reach USD 23.90 billion by 2032, expanding at a CAGR of 14.85% during 2026–2032, according to Strategic Market Research.

 

B-cell maturation antigen (BCMA) has emerged as one of the most important therapeutic targets in multiple myeloma, a plasma-cell malignancy with a high rate of disease recurrence. BCMA is highly expressed on malignant plasma cells while showing limited presence on most normal tissues, making it an attractive target for precision oncology approaches. BCMA-targeted therapies are designed to selectively attack myeloma cells through multiple mechanisms, including CAR-T cell therapy, bispecific antibodies, and antibody-drug conjugates (ADCs).

 

The commercial market is currently driven primarily by relapsed or refractory multiple myeloma (RRMM), where patients have progressed after standard treatment classes such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. BCMA therapies provide new treatment options for these heavily pretreated patients by introducing different immune-based mechanisms. Approved and emerging products include CAR-T therapies such as ciltacabtagene autoleucel and idecabtagene vicleucel, bispecific antibodies including teclistamab, elranatamab, and linvoseltamab, and antibody-drug conjugate approaches such as belantamab mafodotin.

 

In the United States, approximately 36,000 new myeloma cases are expected in 2026, with about 10,850 deaths. An estimated 202,793 people were living with myeloma in 2023, while five-year relative survival reached approximately 63.7% during 2016–2022. Longer survival increases the number of patients progressing through multiple treatment lines and eventually becoming eligible for advanced BCMA-directed therapies.

 

Multiple myeloma primarily affects older adults, creating both opportunity and treatment challenges. The median age at diagnosis is approximately 69 years, with around 66% of cases occurring in individuals aged 65 years or older. While CAR-T therapies can produce deep and durable responses through a personalized one-time infusion, their use may be limited by manufacturing timelines, specialized treatment-center requirements, and patient fitness. Bispecific antibodies and ADCs expand treatment accessibility by providing more readily available administration options, although they require monitoring for immune-related toxicities and other treatment-associated risks.

 

A major growth opportunity lies in the movement of BCMA therapies into earlier treatment lines. Initially approved for patients with highly advanced disease, CAR-T therapies and bispecific antibodies are increasingly being evaluated and approved for patients after fewer prior therapies. Earlier intervention may expand the eligible patient population and allow treatment before disease progression and cumulative therapy exposure significantly weaken immune function.

 

Beyond multiple myeloma, additional applications remain under investigation. AL amyloidosis, a plasma-cell disorder characterized by abnormal light-chain production, represents a promising emerging opportunity for BCMA-targeted approaches, particularly in relapsed or refractory disease. However, current evidence remains limited and the indication is not yet a major commercial contributor. BCMA therapies are also being explored in autoimmune diseases such as lupus and systemic sclerosis by targeting pathogenic antibody-producing plasma cells, but these applications remain experimental.

 

Overall, the BCMA Targeted Therapies Market is transitioning from a late-line multiple myeloma niche into a broader precision immunotherapy platform. Near-term growth will be driven by expanded use in relapsed and earlier-line multiple myeloma, while future opportunities may emerge from plasma-cell disorders and autoimmune diseases. The strongest commercial potential will come from therapies that improve accessibility, extend treatment eligibility, deliver durable responses, and integrate advanced immune-based approaches into routine cancer care.

 

 

Segment Leaders and Growth Frontiers: CAR-T Retains Revenue Leadership as Bispecifics, Earlier-Line Use, Outpatient Care, and Asia-Pacific Accelerate

By Product Type

Leading Subsegment: CAR-T Cell Therapies

CAR-T cell therapies account for a 55% market share, generating USD 5.005 billion in 2025 revenue, and are projected to grow at a CAGR of 12.58% during 2026–2032. BCMA-targeted CAR-T therapies have become a major treatment approach for relapsed or refractory multiple myeloma by genetically modifying patients’ own T cells to recognize and eliminate BCMA-expressing cancer cells. Approved therapies such as idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel) have expanded treatment options for heavily pretreated patients. However, challenges including relapse, antigen escape, manufacturing complexity, and management of cytokine release syndrome continue to influence adoption. Next-generation dual-targeted CAR-T designs, including BCMA combinations with targets such as GPRC5D, are being developed to improve response durability and broaden clinical utility.

Fastest-Growing Subsegment: Bispecific Antibodies and T-Cell Engagers

Bispecific antibodies account for a 38% market share, generating USD 3.458 billion in 2025 revenue, and are projected to expand at the fastest product-type CAGR of 17.97% during 2026–2032. BCMA-targeted bispecific antibodies are off-the-shelf immunotherapies that simultaneously bind BCMA on multiple myeloma cells and CD3 on T cells, activating the patient’s immune system to eliminate cancer cells. Approved therapies including teclistamab (Tecvayli®), elranatamab (Elrexfio®), and linvoseltamab (Lynozyfic™) have expanded treatment options for relapsed or refractory multiple myeloma. Their rapid availability, elimination of apheresis requirements, and simpler administration process provide advantages over personalized CAR-T therapies. However, ongoing focus remains on improving response durability, managing cytokine release syndrome, and optimizing long-term treatment strategies.

 

By Treatment Application

Leading Subsegment: Late-Line Relapsed or Refractory Multiple Myeloma

Late-line relapsed or refractory multiple myeloma (RRMM) accounts for a 68% market share, representing USD 6.188 billion in 2025 revenue, and is projected to grow at a CAGR of 7.16% during 2026–2032. BCMA-targeted therapies have become important treatment options for patients who have progressed after multiple standard therapies, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. BCMA serves as an effective target due to its high expression on malignant plasma cells. Available approaches include CAR-T therapies, bispecific antibodies, and antibody-drug conjugates (ADCs), offering targeted immune-mediated cancer destruction. However, challenges such as treatment resistance, BCMA antigen loss, T-cell exhaustion, cytokine release syndrome, infections, and limited durability of response continue to influence clinical adoption and drive development of next-generation therapies.

Fastest-Growing Subsegment: Earlier-Line Relapsed Multiple Myeloma

Earlier-line relapsed multiple myeloma accounted for a 32% market share, generating USD 2.912 billion in revenue in 2025, and is expected to register the fastest application CAGR of 24.97% during 2026–2032. Growth is driven by the increasing adoption of BCMA-targeted therapies in patients with 1–3 prior lines of treatment, where earlier intervention can improve response depth and progression-free survival. CAR-T therapies, bispecific antibodies, and antibody-drug conjugates are expanding treatment options by offering durable responses, off-the-shelf immune engagement, and targeted cytotoxic approaches while patients maintain better immune fitness.

 

By End User

Leading Subsegment: Hospitals and Academic Medical Centers

Hospitals and academic medical centers represent the leading care settings for BCMA-targeted multiple myeloma therapies, accounting for 72% of the market with USD 6.552 billion in revenue in 2025 and projected to grow at an 11.84% CAGR during 2026–2032. These specialized centers provide advanced infrastructure for CAR T-cell therapy, including cell-processing facilities, apheresis services, lymphodepletion management, and intensive monitoring. They also support bispecific antibody administration, toxicity management for CRS and ICANS, and comprehensive infection prevention, making them essential hubs for high-acuity BCMA therapy delivery.

Fastest-Growing Subsegment: Ambulatory and Outpatient Treatment Centers

Ambulatory and outpatient centers account for 7% of the market, generating USD 0.637 billion in revenue in 2025, and are expected to achieve the fastest end-user CAGR of 22.45% during 2026–2032. Their growing role is driven by the shift of BCMA-targeted therapies, including CAR-T therapies and bispecific antibodies, toward outpatient delivery models. These centers enable safer step-up dosing, long-term maintenance therapy, toxicity monitoring, supportive care, and post-treatment surveillance while improving patient access, reducing hospitalization burden, and lowering healthcare costs through specialized oncology infrastructure and coordinated care pathways.

 

By Geography

Leading Subsegment: North America

North America dominates the BCMA-targeted therapy market, accounting for 48% of global revenue and reaching USD 4.368 billion in 2025, with a projected CAGR of 13.37% during 2026–2032. The region’s leadership is driven by early regulatory approvals, advanced healthcare infrastructure, and rapid adoption of innovative multiple myeloma treatments. CAR-T therapies such as ide-cel and cilta-cel, bispecific antibodies including teclistamab and elranatamab, and emerging ADC approaches are expanding treatment options. Growth is further supported by earlier-line adoption, although logistics, specialized administration, and toxicity management remain key considerations.

Fastest-Growing Subsegment: Asia-Pacific

Asia-Pacific (APAC) represents 20% of the global market, generating approximately USD 1.820 billion in revenue in 2025, and is expected to achieve the fastest regional CAGR of 18.51% during 2026–2032. Growth is driven by the expanding adoption of BCMA-targeted therapies, including CAR-T therapies, bispecific antibodies, and antibody-drug conjugates, for relapsed/refractory multiple myeloma (RRMM). Regional advancement is supported by regulatory progress in China, Japan, and South Korea, growing clinical trial activity, improved specialty care infrastructure, and increasing access to innovative treatments. However, adoption remains influenced by reimbursement disparities, manufacturing capabilities, treatment complexity, and the need for specialized centers to manage therapy-related risks.

 

Market Drivers: Earlier Treatment Access and Scalable Delivery Expand BCMA Therapy Demand

Earlier-Line Approvals Enlarge the Eligible Treatment Population

Regulatory approvals are moving BCMA-directed therapies closer to the first relapse, expanding treatment beyond patients who have exhausted four or more regimens. Idecabtagene vicleucel is indicated after at least two prior treatment lines, while the FDA approved teclistamab combined with daratumumab in March 2026 for patients who had received at least one prior line containing a proteasome inhibitor and an immunomodulatory agent. This movement gives BCMA therapies access to a larger and generally fitter patient population than the original late-line indications.

Clinical evidence is accelerating this shift. In the 587-patient MajesTEC-3 study, teclistamab plus daratumumab reduced the relative risk of disease progression or death by approximately 83%, with a progression-free-survival hazard ratio of 0.17 compared with standard regimens. Earlier use increases the potential duration of therapy for repeat-dose bispecific antibodies and raises the number of patients considered for CAR-T referral, manufacturing, and supportive care. The result is a broader revenue base across drugs, cell-processing services, diagnostics, and specialist treatment centers.

Off-the-Shelf Bispecifics Remove the Manufacturing Wait

Bispecific antibodies address one of the largest commercial limitations of autologous CAR-T therapy: the need to collect, engineer, test, and return patient-specific T cells. Ready-to-administer BCMA-CD3 products can be stocked by treatment centers and initiated without an individualized manufacturing cycle. Their availability is particularly important for patients with rapidly progressing disease who may not remain clinically stable during CAR-T production.

The expanding product portfolio also gives physicians alternatives when CAR-T capacity, patient fitness, or treatment timing creates a barrier. Linvoseltamab achieved a 70% objective response rate in the 80-patient population supporting its FDA approval. Among responders, the estimated proportion maintaining a response was 72% at 12 months. Its dosing frequency can decline from weekly to every two weeks and eventually every four weeks in qualifying responders, supporting sustained revenue while lowering the number of treatment visits required over time.

Deep Responses Sustain Adoption in Treatment-Exhausted Patients

Relapsed or refractory multiple myeloma remains difficult to manage after exposure to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Patients progressing after these major drug classes have fewer effective options and frequently require treatment with a different mechanism. BCMA is strongly expressed across malignant plasma cells, allowing CAR-T cells, bispecific antibodies, and ADCs to address this late-line treatment gap through distinct delivery platforms.

Randomized evidence has strengthened physician and payer confidence in this therapeutic target. In KarMMa-3, ide-cel generated a 71% overall response rate, compared with 42% for standard regimens. Median progression-free survival was 13.3 months with ide-cel versus 4.4 months with standard treatment, representing a hazard ratio of 0.49. These outcomes support continued hospital investment in cell-therapy capacity despite the monitoring, manufacturing, and toxicity-management requirements associated with CAR-T treatment.

A Larger Surviving Myeloma Population Creates Recurring Treatment Need

Multiple myeloma remains an incurable disease for most patients, and treatment commonly involves repeated therapy as remission periods end. The U.S. National Cancer Institute estimates 36,000 new myeloma diagnoses in 2026, while approximately 202,793 people were living with the disease in 2023. Five-year relative survival reached 63.7% for patients diagnosed during 2016–2022, creating a growing population that may progress through several treatment lines and eventually become eligible for a BCMA-directed therapy.

The demand base extends well beyond established North American and European treatment centers. The International Agency for Research on Cancer estimated 81,520 new cases in Asia in 2024, representing 41.6% of worldwide multiple myeloma incidence. Asia also accounted for approximately 214,822 five-year prevalent cases. These figures do not directly represent BCMA-eligible patients, but they identify a substantial underlying population from which future treatment demand can emerge as diagnosis, reimbursement, cell-manufacturing capacity, and specialist-center coverage improve

Overall, BCMA targeted therapy demand is shifting from a small, heavily pretreated population toward a broader treatment ecosystem. Earlier-line approvals increase the eligible pool, bispecific antibodies shorten treatment initiation, strong response data support reimbursement, and expanding regional care capacity brings more relapsed patients into advanced treatment pathways.

 

Market Restraints: Toxicity, Treatment Logistics, and BCMA Resistance Limit Patient Conversion

Immune Toxicities Keep Treatment Concentrated in Specialist Centers

Cytokine release syndrome and neurologic toxicity remain major barriers to broader CAR-T and bispecific-antibody use. The ide-cel prescribing information reports cytokine release syndrome in 89% of 349 treated patients, including Grade 3 or higher events in 7%. CAR-T-associated neurologic toxicity occurred in 40%, requiring close monitoring and immediate access to treatments such as tocilizumab and corticosteroids

These requirements restrict administration to hospitals with trained hematology, neurology, intensive-care, pharmacy, and cell-processing teams. Older patients with poor functional status, organ impairment, uncontrolled infections, or rapidly worsening disease may not qualify for treatment. The resulting gap between clinically eligible and actually treated patients limits market penetration outside large academic and transplant centers.

Infection Risk Raises the Cost of Continuous Immune Engagement

BCMA-directed therapies suppress normal plasma cells and can reduce immunoglobulin levels, weakening protection against bacterial, viral, and opportunistic infections. Continuous T-cell engagement with bispecific antibodies can extend this immune suppression across months of treatment. Providers must therefore add antimicrobial prophylaxis, immunoglobulin monitoring, vaccination planning, laboratory testing, and infection-management services to the treatment pathway.

In the MajesTEC-1 study, serious infections occurred in 30% of teclistamab-treated patients, Grade 3 or 4 infections occurred in 35%, and fatal infections occurred in 4.2%. In the teclistamab-daratumumab combination study, serious and Grade 3 or 4 infections were reported in 54% of patients. These rates can lead to dose interruptions, hospitalization, additional supportive-care expenditure, or permanent discontinuation, limiting the commercial advantage of long-duration dosing.

Patient-Specific Manufacturing Creates Time and Capacity Bottlenecks

Autologous CAR-T therapy requires leukapheresis, shipment of patient cells, genetic modification, quality testing, lymphodepleting chemotherapy, and return of the finished product to the treatment center. Every patient therefore represents an individual manufacturing batch. Production scheduling, vein-to-vein time, transportation, quality release, and limited treatment slots can delay therapy for patients with aggressive disease.

Attrition between cell collection and infusion demonstrates the commercial effect of this process. In one ide-cel clinical-study cohort, 11 of 135 patients, or approximately 8%, did not receive the CAR-T product because of death, disease progression, adverse events, consent withdrawal, or clinical decisions. The reported manufacturing-failure rate was 1.5%, indicating that disease progression and patient deterioration can be as important as production failure. Bridging therapy may control disease during the waiting period, but it adds cost and does not guarantee that the patient will remain eligible for infusion.

Antigen Escape Complicates Sequential BCMA Treatment

Repeated use of therapies directed at the same target creates the risk that surviving myeloma cells will reduce or lose BCMA expression. Other resistance mechanisms include T-cell exhaustion, limited effector-cell fitness, soluble BCMA interference, and changes in the bone-marrow microenvironment. These mechanisms can shorten response duration and reduce the effectiveness of using a second BCMA therapy after failure of the first.

A study of 72 teclistamab-treated patients found that 30 patients, or 42%, had previously received a BCMA-directed therapy. Loss of BCMA expression was identified in three previously exposed patients before teclistamab treatment, and none responded. Although complete antigen loss was uncommon, the finding creates uncertainty around sequencing CAR-T cells, bispecific antibodies, and ADCs. It also increases demand for BCMA-expression testing and alternative targets such as GPRC5D and FcRH5.

Ocular Toxicity Restricts ADC Convenience

BCMA-directed ADCs avoid T-cell collection and can be administered as standardized pharmaceutical products, but their cytotoxic payloads introduce a different safety burden. Belantamab mafodotin can damage the corneal epithelium, causing blurred vision, dry eye, photophobia, and reduced visual acuity. Treatment therefore requires baseline and recurring ophthalmic examinations, coordination between hematology and eye-care specialists, and dose delays or reductions when corneal findings worsen.

In the DREAMM-7 population supporting the 2025 U.S. approval, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 events in 77%. Approximately 83% required a dosage modification because of ocular toxicity. The associated REMS requirements, eye-examination capacity, and frequent dose adjustments limit administration in regions where ophthalmology services are not integrated with oncology care.

Overall, BCMA therapies face a conversion problem rather than a lack of clinical demand. Toxicity excludes vulnerable patients, manufacturing delays reduce CAR-T completion, infection management increases recurring care costs, antigen escape complicates sequencing, and ocular monitoring limits ADC convenience. Market expansion will depend on safer immune-engaging designs, shorter manufacturing cycles, validated sequencing strategies, and treatment protocols that can operate beyond a limited number of specialist centers.

 

Competitive Landscape: Johnson & Johnson Leads with a Two-Platform BCMA Franchise

Johnson & Johnson — Leading Company

Johnson & Johnson holds the strongest commercial position in the BCMA-targeted therapies market because it participates in both major immune-engaging modalities: CAR-T cell therapy through Carvykti and bispecific antibodies through Tecvayli. This dual-platform presence gives the company access to patients requiring a potentially durable, one-time cellular therapy and those needing an immediately available, off-the-shelf treatment.

Carvykti, jointly developed with Legend Biotech, generated approximately USD 1.9 billion in global net trade sales during 2025, establishing it as one of the largest commercial BCMA products. Its competitive position is supported by its use after at least one previous treatment in eligible adults, extending the product beyond heavily pretreated patients into an earlier and commercially larger treatment setting.

Johnson & Johnson has also expanded Tecvayli from late-line monotherapy into earlier combination treatment. In March 2026, the FDA approved Tecvayli plus daratumumab after at least one prior line of therapy. In the 587-patient MajesTEC-3 trial, the combination reduced the risk of disease progression or death by 83% compared with investigator-selected standard regimens; median progression-free survival was not reached, versus 18.1 months in the control arm. This combination of commercial CAR-T scale and an expanding bispecific franchise supports Johnson & Johnson’s leadership position.

Other Companies and Their Market Roles

• Legend Biotech: Serves as Johnson & Johnson’s principal cell-therapy partner for Carvykti, contributing product development, manufacturing expertise and commercialization support. Its role is concentrated around expanding Carvykti production capacity and treatment-center availability rather than maintaining a broad portfolio of separately marketed BCMA therapies.

• Bristol Myers Squibb: Competes in the autologous CAR-T segment through Abecma, the first BCMA-directed CAR-T therapy approved in the United States. Abecma is indicated for adults with relapsed or refractory multiple myeloma after two or more previous lines of therapy, positioning BMS as an established CAR-T competitor in patients progressing after the major standard drug classes.

• Pfizer: Participates through Elrexfio, an off-the-shelf BCMA×CD3 bispecific antibody used in heavily pretreated relapsed or refractory multiple myeloma. Pfizer’s role is to broaden access to BCMA treatment for patients who cannot wait for personalized CAR-T manufacturing or are unable to undergo cellular therapy.

• Regeneron Pharmaceuticals: Strengthens competition in the bispecific-antibody segment through Lynozyfic. In the FDA-reviewed LINKER-MM1 population of 80 heavily pretreated patients, Lynozyfic produced a 70% objective response rate, while an estimated 72% of responders remained in response at 12 months. Its dosing can decrease to once every four weeks in qualifying responders, supporting longer-term outpatient use

• GlaxoSmithKline: Provides modality diversification through Blenrep, a BCMA-directed antibody-drug conjugate approved with bortezomib and dexamethasone after at least two prior treatment lines. In DREAMM-7, the regimen delivered median progression-free survival of 31.3 months, compared with 10.4 months for the control regimen. However, ocular toxicity occurred in 92% of treated patients, making eye monitoring and dose modification important determinants of adoption.

• AbbVie: Is an emerging pipeline competitor through etentamig, an investigational BCMA×CD3 bispecific antibody. The company’s role is centered on developing a potentially less-frequent bispecific treatment and testing it against established therapies in the Phase III CERVINO program. Etentamig does not yet contribute commercial BCMA revenue.

• Arcellx and Kite, a Gilead company: Are jointly developing anitocabtagene autoleucel—or anito-cel—a next-generation BCMA CAR-T candidate. Their role is to challenge established CAR-T products by pursuing deep responses with a distinct binding design and a comparatively low target cell dose. The program remains investigational and represents prospective rather than current market revenue.

Overall, Johnson & Johnson leads the competitive landscape through the commercial scale of Carvykti and the expanding treatment reach of Tecvayli. BMS and Legend Biotech reinforce the CAR-T segment, Pfizer and Regeneron increase off-the-shelf bispecific competition, GSK preserves an alternative ADC pathway, while AbbVie and Arcellx represent potential future market entrants.

 

Analyst Commentary: Access, Durability, and Sequencing Will Define the Next Competitive Cycle

The BCMA-targeted therapies market has moved beyond an experimental late-line treatment category and developed into a central component of multiple myeloma care. Treatment adoption is expanding as CAR-T therapies, bispecific antibodies, and antibody-drug conjugates provide new options for patients who have progressed after established drug classes. The strongest future opportunities are emerging around earlier-line treatment, shorter CAR-T manufacturing timelines, outpatient bispecific delivery, reduced infection burden, and effective therapies for relapse after prior BCMA exposure. Companies that successfully combine durable clinical responses with scalable production, manageable safety, and clear treatment-sequencing evidence will create stronger commercial positions across the multiple myeloma treatment ecosystem.

 

BCMA Targeted Therapies Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 9.10 Billion
Revenue Forecast in 2032	USD 23.90 Billion
Overall Growth Rate	CAGR of 14.85% (2026–2032)
Base Year	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Product Type, By Treatment Application, By End User, By Geography
By Product Type	CAR-T Cell Therapies, Bispecific Antibodies and T-Cell Engagers, Antibody-Drug Conjugates
By Treatment Application	Late-Line Relapsed or Refractory Multiple Myeloma, Earlier-Line Relapsed Multiple Myeloma
By End User	Hospitals and Academic Medical Centers, Specialty Oncology and Hematology Clinics, Ambulatory and Outpatient Treatment Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Earlier-line approvals, off-the-shelf bispecific availability, deep responses in treatment-exhausted patients, expanding surviving myeloma population, and growing specialist treatment capacity
Customization Option	Available upon request